|
Astrazeneca on Friday hailed positive results from a phase-three trial of its asthma treatment breztri aerosphere. Shares in the Cambridge, England-based pharmaceutical company rose 0.5% to 14,980.00 pence on Friday morning in London. The treatment is a single-inhaler, fixed-dose triple-combination of inhaled corticosteroid/long-acting beta2-agonist drugs, and a long-acting muscarinic antagonist. Patients dosed with breztri aerosphere, or budesonide/glycopyrronium/formoterol fumarate, showed ‘statistically significant and clinically meaningful improvements’ against standard therapies, AstraZeneca said. The company had tested the treatment against a dual-combination inhaled corticosteroid/long-acting beta2-agonist known as symbicort, or budesonide/formoterol fumarat. It also compared results to an aerosphere version of symbicort, and to a combination of these treatments. Tests linked breztri aerosphere to ‘improved lung function’, AstraZeneca said, alongside ‘reductions in the annualised rate of severe asthma exacerbations’. Breztri has clearance to treat adults with chronic obstructive pulmonary disease in around 80 countries, including the US, EU, China and Japan. It is under review as a potential asthma treatment in major regions, AstraZeneca said. Sharon Barr, the company’s vice president of BioPharmaceuticals R&D said: ‘With so many patients still experiencing the debilitating effects of uncontrolled asthma, we are excited about the potential for Breztri to improve lung function as well as prevent exacerbations in asthma. Building on its well-established profile in COPD, we hope to bring Breztri to patients with uncontrolled asthma as quickly as possible.’ Copyright 2026 Alliance News Ltd. All Rights Reserved.
|
